Back

Real-world health status changes with mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) - Early findings from COMPASS-HCM

29 August 2025 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Cardiotoxicity and protection: from bench to bedside Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Andrew Wang

Duke University Medical Center, Durham (United States of America)

6 More presentations in this session

Presentation thumbnail
A UK multicentre experience of osimertinib related cardiovascular toxicity: real world patterns, risk stratification and surveillance
Doctor C. Simela (Leeds, GB)
Abstract Slides Video
Presentation thumbnail
Impact of dapagliflozin on cardiac remodeling and sirtuin expression in rats with type 1 diabetes mellitus
Associate Professor M. Okoshi (Botucatu, BR) Miss A. Marreiros (Botucatu, BR)
Abstract Slides Video
Presentation thumbnail
Maternal fluconazole use during the third trimester and risk of QT prolongation in the offspring
Doctor G. Ninh (Herlev, DK)
Abstract Slides Video
Presentation thumbnail
Ranolazine ameliorates palmitic acid-induced insulin resistance in HL-1 cardiomyocytes by Ca2+/ CaMKII modulation: an in vitro investigation and population-based cohort study
Professor P. Liu (Tainan, TW)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of migalastat in Fabry's disease treatment with cardiac impact : a systematic review and meta-analysis
Mr L. Oldra (Sao Paulo, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiotoxicity and protection: from bench to bedside

The Event

Event poster

ESC Congress 2025

29 August 2025 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Mavacamten in hypertrophic cardiomyopathy: use of accessible functional testing to examine real-world effectiveness
thumbnail
Congress Presentation
Real-world symptom and echocardiographic improvement in obstructive HCM patients treated with mavacamten: evidence of favorable disease modification
thumbnail
Congress Presentation
Mavacamten real-world experience: insights from the Dutch HCM Network.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources